You are here

Article Text

Article menu

Download PDFPDF

Review
Updates in the management of cranial dural arteriovenous fistula
  1. Humain Baharvahdat1,
  2. Yinn Cher Ooi2,
  3. Wi Jin Kim1,
  4. Ashkan Mowla2,
  5. Alexander L Coon3,
  6. Geoffrey P Colby1
  1. 1 Neurosurgery, Ronald Reagan UCLA Medical Center, Los Angeles, California, USA
  2. 2 Neurointerventional Radiology, UCLA, Los Angeles, California, USA
  3. 3 Western Neuro, Carondelet Health Network, Tucson, Arizona, USA
  1. Correspondence to Dr Geoffrey P Colby; GColby{at}mednet.ucla.edu

Abstract

Dural arteriovenous fistula (dAVF) accounts for approximately 10% of all intracranial vascular malformations. While they can be benign lesions, the presence of retrograde venous drainage and cortical venous reflux makes the natural course of these lesions aggressive high risk of haemorrhage, neurological injury and mortality. Endovascular treatment is often the first line of treatment for dAVF. Both transarterial and transvenous approaches are used to cure dAVF. The selection of treatment approach depends on the angioarchitecture of the dAVF, the location, the direction of venous flow. Surgery and, to a lesser extent, stereotactic radiosurgery are used when endovascular approaches are impossible or unsuccessful.

  • dural arteriovenous fistulas
  • dAVF
  • embolisation
  • transarterial
  • transvenous
https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

https://doi.org/10.1136/svn-2019-000269

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Twitter @humainbv, @dralexandercoon

    • Contributors HB is involved in writing and editing the manuscript. GPC is involved in editing and reviewing the manuscript. ALC is involved in reviewing the article. YCO and WJK are involved in drafting and preparing figures and tables. AM is involved in drafting and editing the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests GPC is a consultant for Medtronic, Stryker and MicroVention. ALC is a consultant for Medtronic, Stryker, MicroVention and InNeuroCo.

    • Patient consent for publication Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.